Paxlovid – a new oral antiviral pill for treatment of COVID-19 by Pfizer. Nirmatrelvir & ritonavir.

This is a complete new drug review of Paxlovid, an oral antiviral agent used to treat COVID-19. A visual explanation of the drug’s mechanism of action as a protease inhibitor will be shown. The restrictions placed on this new drug due to its emergency use authorization will be outlined. Results of the EPIC-HR study will be discussed and evaluated to determine how effective Paxlovid is against Covid-19. Covered topics include contraindications, drug-drug interactions, precautions, and adverse drug reactions. This is a concise review that hopefully will provide the healthcare professional useful information. Additional News and Links: ** July 6, 2022. FDA authorizes pharmacists to prescribe Paxlovid with certain limitations. https://www.fda.gov/news-events/press... ** June 16, 2022: Paxlovid not shown to be beneficial in relatively healthy low risk individuals. See LA Times article: https://www.latimes.com/science/story... ** May 6, 2022: Additional Paxlovid information: 1) Patient eligibility screening list (including drug drug interactions), 2) Paxlovid Locator Tool. https://www.fda.gov/drugs/news-events... ========================================================== Paxlovid official FDA News release Dec 22, 2021 https://www.fda.gov/news-events/press... Fact sheet for Healthcare providers (contains drug interaction chart) https://www.fda.gov/media/155050/down... Fact sheet for patients (English) https://www.fda.gov/media/155051/down... Fact sheet for patients (Spanish) https://www.covid19oralrx-patient.com... Pfizer Paxlovid website https://www.covid19oralrx-patient.com... Paxlovid FDA FAQ Dec 22, 2021 http://www.fda.gov/media/155052/download